Month: April 2026

ROUYN-NORANDA, Quebec, April 29, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to welcome Ms. Amélie Rouleau to its board of directors (the “Board”), effective immediately. Ms. Rouleau fills the vacancy created by the resignation of Mr. Loic Bureau in January 2026. Amélie Rouleau is a public affairs and strategic engagement executive with over 18 years of experience in the mining and metallurgical sector. She has held key roles within Glencore, notably at the Raglan Mine and in North American copper operations, where she contributed to integrating environmental, social, and governance (ESG) considerations into business decision-making. Recognized for her leadership in complex, high-visibility environments, she has deep expertise in government relations, stakeholder...

RIDGEFIELD, Conn., April 29, 2026 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its first quarter ended March 27, 2026. Financial highlights for the first quarter of 2026:Net sales increased 11.4% to $1.06 billion for the first quarter of 2026 from $950.7 million for the first quarter of 2025. GAAP net income was $17.4 million, or $0.40 per diluted share, for the first quarter of 2026 compared to $10.3 million, or $0.25 per diluted share, in the first quarter of 2025. Adjusted net income per share1 was $0.40 for the first quarter of 2026 compared to $0.25 for the first quarter of 2025. Adjusted EBITDA1 was $60.1 million for the first quarter of 2026...

Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025Strong initial U.S. commercial launch of AQVESME in thalassemia, with 242 prescriptions written as of March 31, 2026Company plans to submit mitapivat sNDA for sickle cell disease in the second quarter of 2026Pipeline advancing to multiple value-driving inflection points in 2026, including two Phase 2 readouts for next-generation PK activator tebapivat$1.0 billion in cash, cash equivalents, and marketable securities as of March 31, 2026CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases,...

MONACO, April 29, 2026 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the first quarter ended March 31, 2026 (“Q1 2026”). I.   PROFITABILITY AND LIQUIDITYQ1 2026 Adjusted Net Income from Continuing operations1 available to common stockholders2 of $76.0 million ($0.63 per share). Q1 2026 Net Income from Continuing operations1 available to common stockholders of $75.3 million ($0.62 per share). Q1 2026 liquidity of $644.4 million3.II.   COMMON DIVIDEND INCREASE Management of the Company announced that it will recommend to the Board of Directors the approval of a dividend increase, beginning with the second quarter of 2026, increasing the quarterly dividend from $0.115 to $0.125 per common share4. III.   ENTERED INTO 16 SHIPBUILDING CONTRACTS BACKED WITH...